Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
UROGEN PHARMA RG (NQ: URGN)
48.01 USD  +1.17 (+2.50%)
Streaming Delayed Price  /  Updated: 3:16 PM EDT, Jul 17, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 103,475
Open 47.00
Bid (Size) 47.99 (100)
Ask (Size) 48.11 (100)
Prev. Close 46.84
Today's Range 45.36 - 48.35
52wk Range 17.07 - 69.57
Shares Outstanding 4,473,373
Dividend Yield N/A
Performance
YTD
+24.25%
+24.25%
1 Month
-13.07%
-13.07%
3 Month
-19.45%
-19.45%
6 Month
+6.57%
+6.57%
1 Year
+166.72%
+166.72%
Top News
More News
UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel™) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it... Read More
from GlobeNewswire News Releases
UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that... Read More
from GlobeNewswire News Releases
More News
Read More
UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award
from GlobeNewswire News Releases
Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and CoStar Group — Discovering Underlying Factors of Influence
from GlobeNewswire News Releases
UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance
from GlobeNewswire News Releases
UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference
from GlobeNewswire News Releases
UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
from GlobeNewswire News Releases
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments
from GlobeNewswire News Releases
UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018
from GlobeNewswire News Releases
UroGen Pharma to Ring the Nasdaq Stock Market Opening Bell
from GlobeNewswire News Releases
Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital — New Research Emphasizes Econo
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X